Drug firm Dr Reddy's Laboratories today said it has launched generic antihistamine desloratadine tablets in the American market.
The company has launched generic desloratadine orally disintegrating tablets in the strengths of 2.5 mg and 5 mg in the US market on January 24, 2013, Dr Reddy's Laboratories (DRL) said in a statement.
This follows approval of its abbreviated new drug application (ANDA) by the US Food & Drug Administration (USFDA), it added.
The tablets are bio equivalent generic version of Schering Corp's Clarinex Reditabs tablets, DRL said.
"Clarinex Reditabs brand had US sales of approximately $5.3 million for the most recent twelve months ending November 2012 according to IMS Health," it added.
Shares of Dr Reddy's Laboratories today closed at Rs 1,942.55 on BSE, up 0.68% from its previous close.
